MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis

被引:91
|
作者
Tian, Rui-Qing [1 ,2 ]
Wang, Xing-Hua [1 ,2 ]
Hou, Juan [1 ,2 ]
Jia, Wei-Hua [3 ]
Yang, Qian [1 ,2 ]
Li, Yi-Xuan [1 ,2 ]
Liu, Min [1 ,2 ]
Li, Xin [1 ,2 ]
Tang, Hua [1 ,2 ]
机构
[1] Tianjin Med Univ, Tianjin Life Sci Res Ctr, Tianjin 300070, Peoples R China
[2] Tianjin Med Univ, Basic Med Sch, Tianjin 300070, Peoples R China
[3] Sun Sat Sen Univ Med Sci, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
CELL-CYCLE; BREAST-CANCER; SMALL RNAS; EXPRESSION; PROLIFERATION; P27(KIP1); ONCOGENES; GENOMICS; HOMOLOG; MIR-222;
D O I
10.1074/jbc.M111.221564
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
MicroRNAs are a class of noncoding RNAs that are similar to 22 nucleotides in length. MicroRNAs have been shown to play important roles in cell differentiation and in cancer. Recently, studies have shown that miR-372 is tumorigenic in human reproductive system cancers. However, we provide evidence that miR-372 acts as a tumor suppressor gene in cervical carcinoma. miR-372 was found down-regulated in cervical carcinoma tissues as compared with adjacent normal cervical tissues. Growth curve and FACS assays indicated that ectopic expression of miR-372 suppressed cell growth and induced arrest in the S/G(2) phases of cell cycle in HeLa cells. We used bioinformatic predictions to determine that CDK2 and cyclin A1 were possible targets of miR-372 and confirmed this prediction using a fluorescent reporter assay. Taken together, these findings indicate that an anti-oncogenic role of miR-372 may be through control of cell growth and cell cycle progression by down-regulating the cell cycle genes CDK2 and cyclin A1.
引用
收藏
页码:25556 / 25563
页数:8
相关论文
共 50 条
  • [1] MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis
    Tianjin Life Science Research Center, Basic Medical School, Tianjin Medical University, Tianjin 300070, China
    不详
    J. Biol. Chem., 29 (25556-25563):
  • [2] Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H
    Higashi, H
    SuzukiTakahashi, I
    Saitoh, S
    Segawa, K
    Taya, Y
    Okuyama, A
    Nishimura, S
    Kitagawa, M
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 237 (02): : 460 - 467
  • [3] Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma
    M Matsumoto
    M Furihata
    T Ishikawa
    Y Ohtsuki
    S Ogoshi
    British Journal of Cancer, 1999, 80 : 256 - 261
  • [4] Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception
    Giarolla, Jeanine
    Holdaway, Kelsey A.
    Nazari, Maryam
    Aiad, Laila
    Sarkar, Bidisha
    Georg, Gunda I.
    FUTURE MEDICINAL CHEMISTRY, 2025, 17 (05) : 607 - 627
  • [5] Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
    Kang, Jian
    Sergio, C. Marcelo
    Sutherland, Robert L.
    Musgrove, Elizabeth A.
    BMC CANCER, 2014, 14
  • [6] Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
    Jian Kang
    C Marcelo Sergio
    Robert L Sutherland
    Elizabeth A Musgrove
    BMC Cancer, 14
  • [7] Phosphorylation of human DNA polymerase λ by the cyclin-dependent kinase Cdk2/cyclin A complex is modulated by its association with proliferating cell nuclear antigen
    Frouin, I
    Toueille, M
    Ferrari, E
    Shevelev, I
    Hübscher, U
    NUCLEIC ACIDS RESEARCH, 2005, 33 (16) : 5354 - 5361
  • [8] Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors
    Rossi, KA
    Markwalder, JA
    Seitz, SP
    Chang, CH
    Cox, S
    Boisclair, MD
    Brizuela, L
    Brenner, SL
    Stouten, PFW
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2005, 19 (02) : 111 - 122
  • [9] Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors
    Karen A. Rossi
    Jay A. Markwalder
    Steven P. Seitz
    Chong-Hwan Chang
    Sarah Cox
    Michael D. Boisclair
    Leonardo Brizuela
    Stephen L. Brenner
    Pieter F. W. Stouten
    Journal of Computer-Aided Molecular Design, 2005, 19 : 111 - 122
  • [10] Identification of cdk2 binding sites on the p27Kip1 cyclin-dependent kinase inhibitor
    Taeg Kyu Kwon
    Albert A Nordin
    Oncogene, 1998, 16 : 755 - 762